Article
A HUWE1 defect causes PARP inhibitor resistance by modulating the BRCA1-∆11q splice variant.
Oncogene - 1 Sept 2023
Pettitt Stephen J, Shao Nan, Zatreanu Diana, Frankum Jessica, Bajrami Ilirjana, Brough Rachel, Krastev Dragomir B, Roumeliotis Theodoros I, Choudhary Jyoti S, Lorenz Sonja, Rust Alistair, de Bono Johann S, Yap Timothy A, Tutt Andrew N J, Lord Christopher J
Abstract excerpt
Although PARP inhibitors (PARPi) now form part of the standard-of-care for the treatment of homologous recombination defective cancers, de novo and acquired resistance limits their overall effectiveness. Previously, overexpression of the BRCA1-∆11q splice variant has been shown to cause PARPi resistance. How cancer cells achieve increased BRCA1-∆11q expression has remained unclear. Using isogenic cells with...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.